Ultragenyx Pharmaceutical Cash Flow Statement

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Jun '26 Jun 30, 2026	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021
Net Income	-586	-575	-569	-607	-707.42	-454.03
Depreciation & Amortization	33	35	36	26	18.22	13.24
Stock-Based Compensation	139	153	158	135	130.38	104.95
Other Adjustments	-45.8	-56	-53	-13	116.49	60.38
Change in Receivables	-71.41	-31	-34	-23	-12.07	-5.43
Changes in Inventories	-12.45	-6	-11	-7	-9.7	-3.12
Changes in Accounts Payable	49	24	47	-1	79.85	32.31
Changes in Other Operating Activities	10	-10	12	15	3.8	-87
Operating Cash Flow	-485	-466	-414	-475	-380.47	-338.7
Operating Cash Flow Growth	-	-	-	-	-	-
Capital Expenditures	-4.22	-6	-7	-44	-116.12	-73.09
Purchases of Intangible Assets	-5	-15	-13	-3	-30	-
Purchases of Investments	-358.5	-186	-409	-526	-614.74	-1,012
Proceeds from Sale of Investments	373	444	413	747	545.08	890.85
Cash Acquisitions	-	-	-	-	-75.03	-
Other Investing Activities	-4	-1	-2	-6	-0.84	-0.94
Investing Cash Flow	40	236	-18	168	-291.65	-195.37
Issuance of Common Stock	5	86	392	387	10.81	119.04
Net Common Stock Issued (Repurchased)	5	86	392	387	10.81	119.04
Other Financing Activities	-	392	7	1	490.4	-0.49
Financing Cash Flow	397	478	399	388	501.21	118.55
Foreign Exchange Rate Adjustments	-4.36	-	4	-2	-1.08	-1.19
Net Cash Flow	-48.49	252	-35	81	-171.98	-416.71
Free Cash Flow	-489.22	-472	-421	-519	-496.59	-411.79
Free Cash Flow Growth	-	-	-	-	-	-
FCF Margin	-68.21%	-70.13%	-75.18%	-119.59%	-136.68%	-117.18%
Free Cash Flow Per Share	-4.87	-4.79	-4.65	-7.06	-7.10	-6.07
Levered Free Cash Flow	-510.63	-538	-492	-618	-731.38	-571.68
Unlevered Free Cash Flow	-456.23	-501.75	-460.89	-578.13	-678.15	-500.27

SEC Filings: 10-K · 10-Q